# Triplebar

> Triplebar is an Emeryville, California biotech company that pairs a high-throughput microfluidic screening platform with AI genomic models to run evolution at hyper-speed. By packing tens of millions of picoliter microreactors onto a palm-sized chip and testing thousands per second, it generates matched genotype-phenotype datasets that let partners optimize cell lines and microbial strains far faster and cheaper than conventional lab work. The platform powers products across food (precision fermentation, cultivated meat) and biopharma (biologics, cell-engaging cancer therapies).

- **Founded:** 2019
- **Headquarters:** Emeryville, California, United States
- **Founders:** Jeremy Agresti (Founder & CTO), Shawn Manchester (CEO (since March 2025)), Maria Cho (Former CEO)
- **Team size:** ~11 employees
- **Products:** Hyper-Throughput Screening Platform, eiCHO, eiMICRO, Biologics / TCR therapies, Precision fermentation & cultivated meat enablement
- **Notable:** Built a screening platform able to test cells three to four orders of magnitude faster than conventional methods., Raised $20M Series A in October 2023 (cumulative funding reported around $25M at the time; later totals cited up to ~$45M)., Signed commercial partnerships with FrieslandCampina Ingredients and Umami Bioworks.

## Products & services

- **Hyper-Throughput Screening Platform** — A microfluidics platform that creates tens of millions of picoliter microreactors on a palm-sized chip and tests thousands per second, generating matched genotype-phenotype datasets to accelerate cell-line and strain optimization.
- **eiCHO** — A best-in-class CHO cell line engineered for biologics production.
- **eiMICRO** — 'CAD for cells' powered by AI models trained on application-specific datasets for microbial strain design.
- **Biologics / TCR therapies** — TCR-based T-cell engaging therapies aimed at cancer treatment.
- **Precision fermentation & cultivated meat enablement** — Optimized microbial strains and animal cell lines for partners making fermented proteins and cultivated meat/seafood.

## Achievements

- Built a screening platform able to test cells three to four orders of magnitude faster than conventional methods.
- Raised $20M Series A in October 2023 (cumulative funding reported around $25M at the time; later totals cited up to ~$45M).
- Signed commercial partnerships with FrieslandCampina Ingredients and Umami Bioworks.
- Won BioMADE support to develop genomic design automation tools.
- Pivoted toward generative AI genomic models while retaining its microfluidic data engine.

## Latest updates

- **2025-03** — Appointed Shawn Manchester as Chief Executive Officer.
- **2024-12** — Released 'A leap into the biology age' video outlining its AI-genomics vision.
- **2023-10** — Closed $20M Series A led by Synthesis Capital to expand across food and biopharmaceuticals.
- **2023-01** — Announced FrieslandCampina Ingredients partnership for precision-fermented dairy proteins.

## Links

- Website: https://triplebar.com
- LinkedIn: https://www.linkedin.com/company/triplebar
- Twitter/X: https://twitter.com/triplebarbio
- YouTube: https://www.youtube.com/channel/UCqLr6TBdpSXq6gDLfDa0ahQ

---

Profile page: https://yespress.io/triplebar
Published by YesPress — https://yespress.io
Last updated: 2026-06-10